683 Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

683 Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.77M	Buy	650,000 +320,000	+97%	+$2.37M	0.33%	62
2026 Q1	$2.03M	Buy	330,000 +50,000	+18%	+$356K	0.11%	106
2025 Q4	$2.02M	Buy	280,000 +50,000	+22%	+$404K	0.09%	107
2025 Q3	$2.35M	Buy	230,000 +11,000	+5%	+$124K	0.12%	104
2025 Q2	$2.28M	Buy	219,000 +69,000	+46%	+$735K	0.15%	101
2025 Q1	$1.98M	Buy	150,000 +25,000	+20%	+$447K	0.14%	108
2024 Q4	$2.24M	Buy	125,000 +49,569	+66%	+$1M	0.14%	88
2024 Q3	$1.22M	Buy	+75,431	New	+$1.18M	0.09%	99
2021 Q1	–	Sell	-23,821	Closed	-$2.17M	–	224
2020 Q4	$2.17M	Hold	23,821	–	–	0.1%	97
2020 Q3	$1.77M	Hold	23,821	–	–	0.13%	85
2020 Q2	$2.03M	Hold	23,821	–	–	0.16%	78
2020 Q1	$1.72M	Buy	+23,821	New	+$2.3M	0.2%	75

Other funds holding RNAC

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

683 Capital Management's RNAC Position: Q2 2026 in Review

683 Capital Management increased its Cartesian Therapeutics (RNAC) stake by 97% in Q2 2026, buying an estimated $2.37M and bringing the position to 650,000 shares worth $6.77M. The position accounts for 0.33% of the portfolio, ranked #62.

683 Capital Management first reported a position in RNAC in Q1 2020 and has held it in 12 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

683 Capital Management held 650,000 shares of Cartesian Therapeutics worth $6.77M as of Q2 2026.
683 Capital Management bought 320,000 Cartesian Therapeutics shares in Q2 2026, an estimated $2.37M.
Cartesian Therapeutics made up 0.33% of 683 Capital Management's portfolio in Q2 2026, its #62 holding.
683 Capital Management first reported a position in Cartesian Therapeutics in Q1 2020 and has held it in 12 quarters since.
95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.